Synairgen (LON:SNG) Hits New 1-Year Low – What’s Next?

Synairgen plc (LON:SNGGet Free Report)’s share price hit a new 52-week low during trading on Friday . The stock traded as low as GBX 2 ($0.03) and last traded at GBX 2 ($0.03), with a volume of 4307056 shares trading hands. The stock had previously closed at GBX 3.75 ($0.05).

Synairgen Trading Down 46.6 %

The business’s fifty day simple moving average is GBX 4.46 and its two-hundred day simple moving average is GBX 4.41. The company has a quick ratio of 6.35, a current ratio of 6.77 and a debt-to-equity ratio of 0.09. The company has a market cap of £4.03 million, a price-to-earnings ratio of -66.67 and a beta of -2.23.

About Synairgen

(Get Free Report)

Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; and IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease.

Read More

Receive News & Ratings for Synairgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen and related companies with MarketBeat.com's FREE daily email newsletter.